Neovascular age-related macular degeneration, often called “wet” AMD, is a condition where abnormal blood vessels grow beneath the retina and leak fluid or blood, damaging the central area of vision. It accounts for only about 10% of all AMD cases but causes 90% of the legal blindness associated with the disease. Without treatment, 76% of affected eyes decline to a visual acuity of 20/200 or worse within three years.
How It Differs From Dry AMD
Most people with age-related macular degeneration have the “dry” form, which makes up roughly 90% of cases. In dry AMD, the light-sensitive cells in the macula gradually break down over years. Neovascular AMD is a more aggressive progression. The body produces excess amounts of a signaling protein called VEGF (vascular endothelial growth factor), which triggers new blood vessels to sprout from the layer beneath the retina, pushing through a thin barrier called the Bruch membrane.
These new vessels are fragile and poorly formed. They leak fluid, proteins, and lipids into and beneath the retina, causing swelling and distortion. They can also rupture and bleed. Over time, the leaking vessels promote scar tissue growth, and that scar tissue permanently destroys the retinal cells responsible for sharp, detailed central vision. Peripheral vision typically remains intact, but the ability to read, drive, or recognize faces can be severely affected.
What Vision Changes Feel Like
The hallmark early symptom is metamorphopsia, a visual distortion that makes straight lines appear wavy or bent. Door frames, text on a page, or the lines on a grid may look curved or uneven. Objects can also appear larger, smaller, farther away, or closer than they actually are. Some people describe it as looking through a pair of glasses with the wrong prescription.
Because the macula handles color detection and fine detail, distortions centered there tend to be more severe than those affecting other parts of the retina. You might notice a blurry or dark spot in the center of your vision while everything around it looks normal. These changes can start in one eye and go unnoticed for a while, especially if the other eye compensates. Many people first realize something is wrong when they cover one eye and discover the other has already lost sharpness.
Who Is Most at Risk
Age is the strongest risk factor, with the condition overwhelmingly affecting people over 50. Smoking is the most significant preventable risk. Current smokers have a two- to four-fold increased risk of developing neovascular AMD compared to people who have never smoked. Data from the Rotterdam Study found risk ratios as high as 6.6 for current smokers, and long-term tracking in the Blue Mountains Eye Study showed a four-fold increase in late AMD risk over 10 years for those still smoking.
Genetics also play a substantial role. Variants in genes related to the complement immune system, particularly a gene called complement factor H (CFH), and another variant known as HTRA1 are well-established risk markers. Having a family history of AMD raises your likelihood, and certain combinations of genetic variants and smoking compound the risk dramatically. Other contributing factors include high blood pressure, obesity, and a diet low in leafy greens and fish.
How It Is Diagnosed
Eye doctors typically start with a dilated eye exam and an Amsler grid test, a simple printed grid of straight lines you look at to detect any waviness or missing areas. The key diagnostic tool is optical coherence tomography, or OCT, which takes cross-sectional images of the retina in extraordinary detail. OCT can reveal fluid pockets within or beneath the retina, detachment of the layer underneath the retina (called the retinal pigment epithelium), and other structural changes invisible to the naked eye.
Doctors look at several specific markers on OCT to judge disease activity and predict how well treatment will work. Fluid trapped within the retinal layers themselves tends to be a worse sign for vision than fluid sitting just beneath the retina. Detachment of the pigment epithelium layer often responds poorly to treatment and is associated with reduced visual performance. Fluorescein angiography, where a dye is injected into a vein and photographed as it passes through the eye’s blood vessels, can also pinpoint the exact location and extent of leaking vessels.
What Happens Without Treatment
Left untreated, the prognosis is poor. Within three years, roughly three out of four eyes reach a level of vision loss classified as legally blind (20/200 or worse). Beyond the immediate damage from leaking vessels, untreated neovascular AMD also leads to permanent tissue destruction called macular atrophy. The cumulative risk of developing this atrophy reaches about 31% at five years, 43% at seven years, and over 61% at ten years.
Once macular atrophy develops, about one-third of eyes have involvement of the very center of vision right from the start. Within three years of atrophy appearing, half of affected eyes have central involvement. This is irreversible loss, meaning even if treatment begins later, that portion of vision cannot be recovered.
How Treatment Works
The standard treatment involves injections directly into the eye to block VEGF, the protein driving abnormal vessel growth. These anti-VEGF injections have transformed outcomes for people with wet AMD over the past two decades, often stabilizing vision and in many cases improving it. The procedure itself takes only a few minutes, with numbing drops applied beforehand. Most people describe feeling pressure rather than sharp pain.
Treatment usually begins with a loading phase of three monthly injections. After that, the interval between injections is gradually extended based on how well the eye responds. This approach, called “treat and extend,” aims to find the longest gap between injections that still keeps the disease under control. With first-generation medications like ranibizumab and standard-dose aflibercept, many patients settle into a pattern of injections every 8 to 12 weeks.
Newer medications have pushed those intervals further. Faricimab works by targeting two different pathways involved in vessel leakage and instability, not just VEGF alone. High-dose aflibercept (8 mg) also delivers a larger amount of the blocking agent per injection. Both have shown they can maintain vision with injections spaced up to 16 weeks apart in clinical trials, meaning some patients need as few as three to four injections per year after the loading phase. For a condition that requires lifelong monitoring and treatment, fewer visits to the eye doctor is a meaningful quality-of-life improvement.
Living With Neovascular AMD
Even with effective treatment, neovascular AMD is a chronic condition. You will need regular OCT scans to monitor for returning fluid, and treatment intervals may need to be shortened if the disease flares. Some people maintain excellent central vision for years on a stable injection schedule. Others experience gradual decline despite consistent treatment, particularly if scar tissue has already formed before therapy began.
Practical adaptations can make a significant difference. Magnifying devices, large-print books, high-contrast settings on phones and computers, and improved lighting at home all help preserve independence. Low-vision rehabilitation specialists can help you learn techniques to make the most of remaining vision. Because the disease affects central vision while leaving peripheral vision intact, most people continue to navigate their environment, even if tasks requiring fine detail become difficult.
If you have dry AMD in one or both eyes, monitoring for the sudden onset of distortion or a new blurry patch is important. Catching the transition to neovascular AMD early, before significant scarring occurs, gives treatment the best chance of preserving vision long-term.